BioRefer LABORAT pence FINAL REPORT &? OPKO Health Company , ORSHER, STUART EPSTEIN, JEFFREY ° DOB; 21/20/1953 Age: 64 y Sex: 4 U/FL: Bed: | Rm: Patient ID: | Address:9 EAST 71ST STREET, NEW YORK, NY 16823 3876 - STUART ORSHER, M.D. Notes: NON FASTING NOTE: SST tube submitted was inadequately spun. Serum was found to contain RBCs. Certain tests, e.g. Glucose, May be decreased while ae others e.g. Potassium or LOH may be elevated. ) CLINICAL REPORT Clinical Abnormalities Summary: (May contain al) abnor: $3 S msy not have abnormal Cholesterol 224 HI Triglycerides HDL CHOL., DIRECT 29 Lo HDL as X% of 13 * Chol/HOL Ratio 7.7 * NON-HDL i95 HI Cholesterol CHOLESTEROL HEP. A Ab., TOTAL Reactive * HEP, B SURF. AB. Reactive * 250H, VITAMIN D 31.5 LO PTH(3), INTACT 106.6 HT PNEUMO Ab TYPE 1 6.3 Lo PNEUMO Ab TYPE 4 6.8 LO (58) (58) PNEUMO Ab TYPE 8 @.6 LO PNEUMO Ab TYPE 9 (9N) @.7 LO PNEUMO Ab TYPE 12 (12F) (58) (58) (58) PNEUMO Ab TYPE 19 (19F) 1.1 Lo PNEUMO Ab TYPE 23 (23F) 8.3 LO PNEUMO Ab TYPE 26 (6B) @.9 LO (58) (58) (58) PNEUMO Ab TYPE 68 (9V) @.5 LO B.Henselae IgG Ab 1:64 * (58) (3) Albumin 88/30/2017 Calcium ~ i gg ~ _ — a ‘9.7 | ey3e7207 ~~ 224 HI 08/26/2017 “Triglycerides ero a 08/30/2617 HDL CHOL., DIRECT 29 Lo 08/30/2617 “WOL as % of Cholesterol ~~~ BF a 0873072817 ' Evaluation: ABOVE AVG. {MODERATE RISK) Chol/HDL Ratio 7.7 * <7.4 | TNP 08/30/2617 Evaluation: ABOVE AVG. (MODERATE RISK) UDLJHDL Ratio aE BT <3.56 0° ~~ en TWP | 0873672617" NON-HDL CHOLESTEROL “495 HT <136 Lr oe IDL Cholesterol Can't Calc <168 mg/dL _ Can"t Cate” | 08/38/2817 ~ NOTE: Unable to calculate LDL due to a Triglyceride level of greater than 400 mg/dL. VLDL, CALCULATED Can't Cale 7-32 ng/dt | Can't Cale | @8/36/2017 BioReference Laboratories, Inc. James Weisberger M.D. Page 1 of s 481 Edward H. Ross Dr | Elmwood Park, NI 07407 | Laboratory Director Printed 99/22/2017 69:57 EFTA00299765

--=PAGE_BREAK=--

BioReference FINAL REPORT LABORATORIES an OPKO Heath Company ORSHER, STUART EPSTEIN, JEFFREY DOB: 01/2/1953 Age: 64 Y Sex: 4 U/FL: Bed: | Patient ID: | dress: 9 EAST 71ST STREET, NEW YORK, NY 16021, Specimen ID: 104659439 Date OF Report: 99/21/2017 16:88 ate Collected: 49/15/2017 a8:57 Date Received: 09/15/2017 23:06 (C3876 - STUART ORSHER, M.D. NEW YORK, NY 10622 Acct #: (C3078) MO P: Can't Calc: One or more components was outside the measurable range. We are unable to calculate. 1.778 8.178-4.536 uIU/mL 68/38/2017 THYROXINE (T4) 2 ae 1. ae ug/dt 68/30/2017 _ T3 UPTAKE (T3U) 31.0 24.3-39.8 % 88/38/2017 “THYROXINE, FREE (FTA) °° Taz BBLS gia 38/38/2617 FREE T4 INDEX 2.3 1.5-3.8 88/38/2017 ‘TS (THYRONINE), TOTAL “> gFO 72-488 gat 08/367 2017 HEP, A Ab., Igm Non- Non-Reactive Reactive NOTE: Hep A Ab,IgM is positive or reactive during the acute phase. Hep A Ab/Total is positive or reactive during the recovery phase or is indicative of a past infection. HEP. A Ab., TOTAL ~~ ~~ Reactive *”iion-Reactive ~~ T 68/36/2017 — HEP. B CORE Ab. IGG Non- Non-Reactive 08/30/2017 Reactive HEP. 6 SURF. AB. ~ Reactive * “Non-Reactive ~ 8873872017 HEP. B SURF. &G Non- = Non-Reactive 68/30/2017 Reactive HEP, BE AB. - “Negative” ~~ "Negative ~ HEP. BE AG. Negative Negative 68/30/2817 TESTOSTERONE, TOT.,S. a ~ {9308-74656 a ‘| 0873072017 ~ NOTE: Patients. receiving the drug Nandrolone cannot be tested for TESTOSTERONE, total using the ETA method (test code 0379-8) due to a strong interference from the drug. Clinicians are asked to request Testosterone, Total by LC/MS/MS (test code 3451-6) for these patients. SEX HORM. BIND.GLOB. 14 16-57 nmol/L FREE TESTOSTERONE ~~ 5264 ~~ 38.88-15¢.68° pg/ml _ LH 3.8 : 1.7-8.6 “mIU/mL FSH . 4,2 1.5-12.4 7 mIU/mL ~ — cK 288 39-328 U/L 345 HI 68/36/2017 © B QUINTANA BE G/M-(30)° SEE ELBIT “SEE BELOW | 873072617 — 8. quintana Ab, IgM < 1:16 ~-INTERPRETIVE INFORMATION: Bartonella quintana Ab, Igm ~~ Less than 1:16 ...... Negative-No significant level of BioReference Laboratories, Inc. James Weisberger M.D. Page 2 of 5 481 Edward H. Ross Dr | Elmwood Park, NJ 07407 | [i a' Laboratory Director = Printed 09/22/2017 09:57 EFTA00299766

--=PAGE_BREAK=--

BioRefere LABORATO DCS FINAL REPORT 60 OPKO besith Company JORSHER, STUART EPSTEIN, JEFFREY Date OF Report: @8/21/2617 16:68 C3078 - STUART ORSHER, M.D. : : | Bp@oate Collected: 9/15/2017 08.57 9 EAST 79TH ST, Patient Id: INEW YORK, NY 19021 Address:9 EAST 71ST STREET, Acct #: (C3070) NEW YORK, NY 10821 P: INICAL REPORT Bartonella quintena TEM antibody detected. -* 1:16 or greater ..... Positive-Presence of IgM antibody «= to Bartonella quintane detected, _ Suggestive of current or recent -- infection, ~-The presence of IgM antibodies Suggests recent infection. Low --levels: of IgM antibodies may occasionally persist for more than 12 i ssmonths post-infection. ~-Test developed and characteristics determined by ARUP ~-Laboratories. See Compliance Statement A: aruplab.com/cs ~-we.aruplab.cam, Julio Delgado, MD - Lab, Director B. quintana Ab, Ig6 <1:64 ~- INTERPRETIVE INFORMATION: Bartonella quintana Antibody, IgG ~- Less than 1:64 ....... Negative: No significant level of -- Bartonella quintena IgG antibody ~ detected. ws 4564 - 13228 ..,...... Equivocal: Questionable presence ws of Bartonella quintana Ig6 -- antibody detected. Repeat testing -- in 16-14 days may be helpful. = 2:256 or greater ..... Positive: Presence of IgG = antibody to Bartonelle quintana i detected, suggestive of current -- or past infection, --A low positive Suggests past exposure or infection, while high --positive results may indicate recent or current infection, but is ~-inconclusive for diagnosis. Seroconversion between acute and --convalescent sera is considered strong evidence of recent --infection. The best evidence for infection is a significant change ~-On tWO appropriately timed specimens where both tests are done in ~-the same laboratory at the same time. ~-Test developed and characteristics determined by ARUP ~-Laboratories. See Compliance Statement A: @ruplab.com/cs HEP. C Ab, Non- Non-Reactive TNE 68/30/2617 Reactive . HEP C Ab. {(S/€O RATIO) "}.a3 ~ <6.88 _ : TAP 8/30/2017 (38) Performed by: ARUP i 566 Chipeta way ' Salt Lake City, UT s841e8 Hepatitis B Result Interpretation (for reference use only) Marker LI/EA* Acute Past Chronic HBV Vacc. AONMESESERMRERS SESS OHESE SEL ANERA EEE CARRERE ES eS EHEREKESe SHAKE EES ENE HBsAg + + ~ + - BioReference Leboratories, Inc. James Weisberger M.D. Page 3 of 65 481 Edward H. Ross Dr | Elmwood Park, NJ 07407 | Laboratory Director Printed 98/22/2017 09:37 EFTA00299767

--=PAGE_BREAK=--

BioReference FINAL REPORT LABORATOR) Es an OPKO Health Company - ORSHER, STUART EPSTEIN, JEFFREY DOB: @1/29/1953 Age: 64 y Sex: mM} C3870 - STUART ORSHER, M.D. U/FL: Bed: ate Collected: 99/15/2017 08:57 Rm: | Date Received: 09/15/2017 23:66 Patient ID: | INEW YORK, NY 10021 Address:9 EAST 71ST STREET, | Acct #: (C3870) NEW YORK, NY 10621 iP: North America Eastern Time eng + HEP.B,CORE AB, IgM * - - - HEP.B.CORE AB, - + + + . HBeab - - +/- +/- - HBsAb - - +/= . + *Late Incubation/Early Acute NOTE: In remote. past infection, HBsAb level may be Negative or Non-Reactive in some patients. FOLIC ACID 7.77 >5.38 ng/aL | TNP | 08/30/2017 Folic Acid Range Units (ng/mL) Normal 28.38 Borderline deficient 3.38-5.38 Deficient @.35-3,37 Excessive >24.08 VITAMIN B12 355 — : 211-91 - ‘pe/ai oa “INP” ) 68/38/2817 250H, VITAMIN D 31.5 LO 32.6-100.¢ ng/mL | TNP 08/36/2017 VITAMIN D,25-0H TEST INFORMATION Range (ng/mL) Suggested Interpretation <20.8 Deficient 26.@-31.9 Insufficient 32.6-188,0 Sufficient 2188.8 Possible Adverse Effects ‘VIT D1, 2501HVoROMY 52.6 0° °° : “49°9-79,3° pg/ml TP 0673072857" PTH(3), INTACT 106.8 HI 13.8-85,4 pe/mL TNP 08/38/2017 “PNEUMO AB TYPE I (58) eg bs rT 77 a 6,3 10 08/38/2617 _ PNEUMO Ab TYPE 3 (58) 1.8 >1.3 ug/ml 1.4 08/36/2017 'PNEUMO Ab TYBE 4 (8) OSLO SL “Ug7at ~ 8.6 LO” 68/38/2817 PNEUMO Ab TYPE 8 (58) 8.6 LO >1.3 ug/mL 6.4 10 88/30/2617 ‘PREURO Ab TYPE S (SN) (58) este “SL ga “6.4 LO | 878672017 ~~ PNEUMO Ab TYPE 12 (12F) (58) <0.3 LO >1.3 ue/mL <@.3 LO | 03/30730i7 | “PNEUMO Ab TYPE 4 (58) 33630000» ~ug/ ie “33.2 | 8/3/2017 PNEUMO Ab TYPE 19 (19F) (58) 1.1 Lo 24.3 ug/l 6.8 LO 08/30/2017 "PNEUMO Ab TYPE 23 (23F) (58) ~~ ~~" 6 LO" 31.37 ge 6.3 1 —F 08/38/2617 PNEUMO Ab TYPE 26 (6B) (58) @.9 LO 1.3 ug/mL 6.5 LO 8/30/2017 “PNEUMO Ab TYPE 5 (58) 7 Ch oi ug/l 7.8 | 873878 PNEUMO Ab TYPE 51 (7F) (58) 1.9 >1.3 ug/mL 1.5 08/38/2617 “PNEUMO Ab TYPE 56 (18¢) (58) i.e — 31.3 ~~ tg/mi "773 bo) easeraers PNEUMO Ab TYPE 68 (9V) (58) 8.5 Lo >1.3 ug/m @.4 LO 8/30/2017 *This test was developed and its performance characteristics determined by BioReference Laboratories, Inc. James Weisberger M.D. Page 4 of 5 481 Edward H. Ross Or | Elmwood Park, N3 07497 ; Laboratory Director Printed 99/22/2017 69:57 EFTA00299768

--=PAGE_BREAK=--

BioReference FINAL REPORT LABORATORIES an OPKD Health Company EPSTEIN, JEFFREY DOB: 91/24/1953 Age: 64 y Sex: » | U/FL: Bed: | Rm: Patient Ip; ! Address:9 EAST 73ST STREET, NEW YORK, NY 10021 Specimen ID: 164659439 Date OF Report: 29/21/2017 10-¢8 Date Collected: 09/15/2017 08:57 Date Received: 99/15/2617 23:06 CLINICAL REPORT Viracor Eurofins. Tt has not b Drug Administration. Testing Performed at: Viracor Eurofins 1681 NW Technology Drive Lee's Summit, MO 64986 CLIA® 260-8983643 'B.Henselae IgG Ab (3) 1:64 * < 1:64 titer 1:64 * 68/38/2017 B.Henselze IgM Ab (3) <1:26 < 1:20 titer . «1:28 68/36/2617 This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Valencia. It has pot been cleared or approved by the US Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. (3) Performed by: Quest Diagnostics Nichols Institute of Valencia 27027 Tourney Road Valencia, CA 91355-5386 (58) Performed by: Viracor Eurofins Clinical Diagnostic 1081 NW Technology Drive Lees Summit, MO 6486 NOTE: Specimen submitted is LIPEMIC, This may cause 4naccurste results. Please resubmit a fasting specimen at your earliest convenience. BioReference Laboratories, Inc. James Weisberger M.D. Page 5 oF 5 481 Edward H. Ross Or | Elmwood Park, N) 67407 mi) Laboratory Director printed 99/22/2017 09:57 EFTA00299769